Biological Bank for Atrial Fibrillation and Stroke (BAFA)

Civil Hospices of Lyon

Status: Enrolling

Conditions: Atrial Fibrillation; Stroke

Treatments: Genetic: Blood taken

Study type: Observational

Funder types: Other

Identifiers

NCT03611816

2017-A03327-46 (Other Identifier)

69HCL17_0538

Details and patient eligibility

About

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years.

According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted.

The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Group 1a

• Inclusion Criteria :

  • AF history

• Exclusion Criteria :

  • No AF history
  • patient who didn't signed consent

Group 1b

• Inclusion Criteria :

  • AF history
  • Scheduled electrophysiological exploration or AF ablation

• Exclusion Criteria :

  • No AF history
  • pregnant women
  • patient who didn't signed consent

Group 1c

• Inclusion Criteria :

  • AF/AT history
  • Stroke history

• Exclusion Criteria :

  • No Stroke history
  • patient who didn't signed consent

Group 2

• Inclusion Criteria :

  • patient over 80
  • ECG: sinusal rhythm
  • TTE : no left atrial dilatation

• Exclusion Criteria :

  • atrial fibrillation history
  • TTE : Left atria >25cm², > 34m/m2), FEVG < 50%
  • ECG : QRS > 90 ms
  • cardiac pathologies (excepted hypertension and valvulopathies)
  • History of stroke and transient ischemic attack
  • patient who didn't signed consent

Group 3

• Inclusion Criteria :

  • cryptogenic stroke or transient ischemic attack history before 50 yo
  • No AF history

• Exclusion Criteria :

  • AF history
  • stroke or transient ischemic attack over 50 yo
  • patient who didn't signed consent

Trial design

1,000 participants in 5 patient groups

Group 1a

Description:

Patient with atrial fibrillation and without stroke history.

Treatment:

Genetic: Blood taken

Genetic: Blood taken

Genetic: Blood taken

Group 1b

Description:

Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.

Treatment:

Genetic: Blood taken

Genetic: Blood taken

Genetic: Blood taken

Group 1c

Description:

Patient with atrial fibrillation and with stroke history.

Treatment:

Genetic: Blood taken

Genetic: Blood taken

Genetic: Blood taken

Group 2

Description:

Patients aged over 80 years old and without history of atrial fibrillation.

Treatment:

Genetic: Blood taken

Genetic: Blood taken

Genetic: Blood taken

Group 3

Description:

Patient with cryptogenic stroke or transient ischemic attack history before the age of 50.

Treatment:

Genetic: Blood taken

Genetic: Blood taken

Genetic: Blood taken